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Abstract Parkinson’s disease (PD) and multiple system atro-
phy (MSA) are both part of the spectrum of neurodegenerative
movement disorders and α-synucleinopathies with overlap of
symptoms especially at early stages of the disease but with
distinct disease progression and responses to dopaminergic
treatment. Therefore, having biomarkers that specifically clas-
sify patients, which could discriminate PD from MSA, would
be very useful. MicroRNAs (miRNAs) regulate protein trans-
lation and are observed in biological fluids, including cerebro-
spinal fluid (CSF), and may therefore have potential as bio-
markers of disease. The aim of our study was to determine if
miRNAs in CSF could be used as biomarkers for either PD or
MSA. Using quantitative PCR (qPCR), we evaluated expres-
sion levels of 10 miRNAs in CSF patient samples from PD
(n = 28), MSA (n = 17), and non-neurological controls
(n = 28). We identified two miRNAs (miR-24 and miR-205)
that distinguished PD from controls and four miRNAs that
differentiated MSA from controls (miR-19a, miR-19b, miR-
24, and miR-34c). Combinations of miRNAs accurately dis-
criminated either PD (area under the curve (AUC) = 0.96) or
MSA (AUC = 0.86) from controls. In MSA, we also observed
that miR-24 and miR-148b correlated with cerebellar ataxia
symptoms, suggesting that these miRNAs are involved in cer-
ebellar degeneration in MSA. Our findings support the
potential of miRNA panels as biomarkers for movement dis-
orders and may provide more insights into the pathological
mechanisms related to these disorders.
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Abbreviations
AUC Area under the curve
CSF Cerebrospinal fluid
Ct Cycle threshold
GM Geometric mean
miRNA microRNA
MSA Multiple system atrophy
PD Parkinson’s disease
qPCR Quantitative PCR
REL Relative expression
ROC Receiver operator characteristics
Introduction
Parkinson’s disease (PD) is the second most common neuro-
degenerative disorder in elderly people, characterized by the
loss of dopaminergic neurons, resulting in a movement disor-
der with symptoms such as postural instability, bradykinesia,
rest tremor, and rigidity [1]. Non-motor symptoms are also
reported, such as neuropsychiatric dysfunction, cognitive im-
pairment, sleep disorders, olfactory dysfunction, sensory
symptoms, and pain [2]. Multiple system atrophy (MSA), a
rare, rapidly progressive, and very debilitating disease, is char-
acterized by parkinsonism or cerebellar ataxia, in combination
with autonomic dysfunction. Furthermore, both diseases are
part of the spectrum of α-synucleinopathies, characterized by
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accumulation of the proteinα-synuclein in Lewy bodies as the
major neuropathological hallmark. Due to the overlap of
symptoms with PD at early stages, MSA may be
misdiagnosed as PD. At later stages, MSA has, however, a
distinct disease progression and usually poor response to anti-
Parkinson treatment [3].
The diagnoses of PD or MSA are based on extensive
clinical and neurological evaluations, cerebral MRI, and
response to anti-Parkinson treatment [4, 5]. Biomarkers
that specifically classify patients with PD and discrimi-
nate them from other atypical parkinsonism, such as
MSA, are not yet available. A reliable biomarker to com-
plement clinical diagnoses would be very useful prefera-
bly at early stages of diseases to avoid misdiagnoses, pro-
vide adequate disease management and patient counsel-
ing, and for research purposes.
Cerebrospinal fluid (CSF) is the body fluid which is closest
to the brain, and therefore, it is the most promising body fluid
for identification of biomarkers for neurodegenerative disor-
ders. Several proteins have been investigated in CSF as bio-
markers for PD and atypical parkinsonism disorders, such as
neurofilament light chain (NFL), tau, α-synuclein, and Aβ42
[6]. NFL and total tau protein levels discriminate MSA from
PDwith reasonable accuracy [7–9], whereas CSFα-synuclein
is reduced in all α-synucleinopathies and Aβ42 was investi-
gated as an indicator of cognitive decline (reviewed in [10]).
MicroRNAs (miRNA or miR) have been investigated and
suggested as biomarkers in a large variety of diseases, includ-
ing neurodegenerative disorders [11]. They are small non-
coding RNAs, of approximately 20 nucleotides, that act in
post-transcriptional regulation of messenger RNA (mRNA),
blocking the translation into proteins by binding to the 3′
untranslated region (3′UTR). A single miRNA can downreg-
ulate the expression of hundreds of genes, and in turn, each
mRNA could be controlled by numerous miRNAs [12].
In the past years, the discovery of circulating miRNAs in
body fluids caught the attention of researchers due to the op-
portunity to use them as biomarkers of disease [13]. Since
then, in the field of neurodegeneration, they have been studied
in brain tissue, serum, plasma, blood, and CSF [14].
Several miRNAs have been identified at abnormal levels in
PD and MSA and suggested as potential biomarkers. For exam-
ple, miR-34b/c [15], miR-133b [16], and miR-205 [17] were
found at lower levels in brain tissue from PD patients compared
to controls. miR-19a/b [18–20] and miR-30c [18, 21] showed
lower expression levels either in PD orMSA in CSF, serum, and
peripheral blood mononuclear cells (PBMC), while concentra-
tions of miR-132 [20] were higher in CSF of PD compared to
controls. In addition, miR-24 and miR-148b were found at al-
tered levels in serum of PD and MSA patients [21].
The aim of our study was to determine if these miRNAs
could be used as disease-specific biomarkers for either PD or
MSAwhen quantified in CSF.
Methods
Cerebrospinal Fluid Samples from Patients and Controls
Our patients were selected from a previous longitudinal study
at the Radboud University Medical Center (Nijmegen, the
Netherlands), which included patients referred to our tertiary
movement disorder center between January 2003 to
December 2006 [22]. These patientswere followed for 3 years,
and the final diagnosis for each patient was established by two
neurologists who were experts in movement disorders based
on the current criteria for PD [5] and MSA [4]. The disease
severity was evaluated using the Hoehn and Yahr (H&Y)
scores [23], the Unified Parkinson’s Disease Rating Scale
(UPDRS) [24], the International Cooperative Ataxia Rating
Scale (ICARS) [25], and the Mini-Mental State Examination
(MMSE) [26]. An overview of the patients’ details is given in
Table 1.
The control group consisted of patients aged above 50,
which resembles the age when symptoms of PD or MSA are
usually observed. These patients had been evaluated by the
Neurology Department for suspicion of neurological disorders
but turned out not to have a neurological disease after exten-
sive investigation.
For selection of CSF samples, we adhered to the following
criteria: leukocyte number count fewer than 5 cells/μl and
erythrocyte number fewer than 200 cells/μl to avoid blood
contamination of CSF, since we previously observed that the
presence of blood cells in CSF affects miRNA levels [27–29].
CSF samples from PD, MSA, and non-neurological controls
were collected in polypropylene tubes, centrifuged, aliquoted,
and stored at −80 °C until further analysis. All participants
provided written informed consent.
RNA Isolation, Reverse Transcription, and Quantitative
PCR
CSF samples from PD (n = 28), MSA (n = 17), and non-
neurological controls (n = 30) were randomly distributed in
three groups for the procedures of RNA isolation, reverse
transcription into cDNA, pre-amplification, and quantitative
PCR (qPCR) as previously described by our group [27, 28]. In
addition, three samples were used as an inter-plate control for
qPCR reactions to determine inter-plate variation in miRNA
quantification.
Our selection of miRNAs was based on previous publica-
tions on these miRNAs, in which they were proposed as po-
tential biomarkers for PD or MSA, either in body fluids or in
brain tissue. We also took into consideration that the predicted
targets of these selected miRNAs should include genes that
had been previously linked to PD or MSA. For this, we sub-
mitted our miRNA selection to the target prediction program
TargetScan version 7 [30], including results of all conserved
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and poorly conserved sites, and for a second confirmation of
target prediction, we submitted the selection to the microT-
CDS software from the DIANA online platform [31, 32], with
a settled threshold of 0.7 (suggested by the software for opti-
mal accuracy on target prediction). An overview of the pre-
dicted targets is listed in Table 2.
The selected miRNAs for this study were as follows: hsa-
miR-19a-3p, hsa-miR-19b-3p, hsa-miR-24-3p, hsa-miR-30c-
5p, hsa-miR-34b-3p, hsa-miR-34c-5p, hsa-miR-132-5p, hsa-
miR-133b, hsa-miR-148b-3p, and hsa-miR-205-5p. In addi-
tion, has-miR-16-5p and U6 small nuclear RNA (snRNA)
were used as reference RNAs. The primer sequences from
Applied Biosystems (Foster City, CA, USA) can be found at
http://www.appliedbiosystems.com.
Data Analysis
ThemiRNA expression levels were normalized to the geomet-
ric mean (GM) [27] of the cycle threshold (Ct) values of two
small reference RNAs in each sample, i.e., miRNA-16 and
U6. The Ct values of these two small reference RNAs were
similar in the three groups. To calculate the relative expression
levels (RELs), we first calculated the GM by the formula
GM ¼ ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃCt miR16½   Ct U6½ p and then calculated the differ-
ence between the Ct values of the miRNA target and the GM
(ΔCt = CtmiRNA −GM). Finally, we calculated the relative
expression by REL = 2−ΔCt.
Data were analyzed using GraphPad Prism, version 5
(La Jolla, CA, USA), and IBM SPSS Statistics 22
(Armonk, NY, USA). D’Agostino and Pearson omnibus
normality test was used to check data distribution. For
comparison among the three groups, in the case of para-
metric data, one-way analysis of variance (ANOVA) was
used with Bonferroni’s post hoc test, and for non-
parametric data, Kruskal-Wallis test with Dunn’s post
hoc test for multiple comparisons. For comparison be-
tween PD and MSA, Student’s t test or Mann-Whitney
U test was selected for parametric and non-parametric
distributed data, respectively. Analyses of covariance
(ANCOVA) were performed to control for possible con-
founding factors that could influence miRNA expression
level, such as age.
Analysis of receiver operator characteristic (ROC) was
performed to assess the diagnostic accuracy of parameters.
The Youden index was used to determine the optimal cutoff
values. To test if a combination of miRNAs could improve
differentiation between groups, binary logistic regression
analysis was applied including all miRNAs and a model
was created for each pair of comparison, which was subject-
ed to ROC curve analysis for test of accuracy.
We also performed a correlation analysis of the miRNAs
in the three groups and also between miRNA expression
levels in PD or MSA and clinical parameters (H&Y,
UPDRS, ICARS, MMSE); for all analyses, we used
Spearman’s rho test.
Table 1 Patient group
characteristics Control PD MSA p value
a
Number 28 28 17
Gender (men/women) 15/13 21/7 13/4 p = 0.15
Age at inclusion (years) 62.9 ± 8 54.5 ± 10.4 62.5 ± 9.7 p = 0.002
Disease duration (months) NA 38.9 ± 40.2 25.7 ± 14.5 p = 0.66
Follow-up (years) NA n = 24 n = 11 NA
4.8 ± 2.1 3.1 ± 1.2
Disease severity p valueb
H&Y score NA n = 27 n = 17 p = 0.05
1.8 ± 0.6 2.1 ± 0.8
UPDRS score NA n = 26 n = 17 p = 0.17
25.1 ± 14.3 29.2 ± 11.7
ICARS score NA n = 26 n = 14 p < 0.0001
1.9 ± 3.2 9.9 ± 7.5
MMSE score NA n = 27 n = 16 p = 0.79
28.1 ± 1.8 27.6 ± 3.2
Values are expressed as mean ± standard deviation
n number of samples, PD Parkinson’s disease,MSAmultiple system atrophy, NA not applicable,H&YHoehn and
Yahr score, UPDRS Unified Parkinson’s Disease Rating Scale, ICARS International Cooperative Ataxia Rating
Scale, MMSEMini-Mental State Examination
a Parameters were analyzed with ANOVA using Bonferroni’s post hoc test, except for gender, which was analyzed
using chi-squared test
b Comparison between PD and MSAwas performed using Student’s t test or Mann-Whitney U test
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Results
MiRNA Expression in CSF
We evaluated the expression levels of ten miRNAs (miR-19a,
miR-19b, miR-24, miR-30c, miR-34b, miR-34c, miR-132, miR-
133b, miR-148b, and miR-205) in CSF of patients diagnosed
with PD or MSA and non-neurological controls. In accordance
to our selection criteria, CSF leukocyte and erythrocyte number
did not differ between groups. Gender distribution was equal in
the three groups, but age was significantly different among
groups, due to the inclusion of relatively young patients in the
PDgroup. The parameters used for evaluation of disease severity,
H&Y, UPDRS, andMMSE scores were similar between PD and
MSA, except for the ICARS score, which is expected since
cerebellar ataxia is prominently observed in MSA and not in
PD. A summary of these parameter details is shown in Table 1.
The selected reference RNAs could be detected in all
samples with the exception of two samples (both from the
control group). Failure to quantify these small RNAs is
probably due to improper sample processing, despite care-
ful execution of our protocols, and therefore, we excluded
these samples from further analysis. The mean Ct values
of miRNA-16 (control = 23.6, PD = 22.1, MSA = 22.1)
and U6 (control = 26.9, PD = 26.2, MSA = 26.2) were
similar in the three groups (ANOVA p = 0.90, p = 0.06,
respectively; data not shown).
MiR-132 could not be detected in any sample and
therefore had to be excluded from further analysis. An
overview of the results for the nine remaining miRNA
targets is shown in Fig. 1. Our findings indicated that
the mean miR-205 levels were upregulated in PD com-
pared to the control group (p = 0.0061; Fig. 1a) by a
factor of 4.1. In contrast, miR-24 was downregulated in
PD by a factor of 3.1 (p = 0.0024; Fig. 1b). Four miRNAs
showed lower levels in MSA compared to controls, miR-
19a (p = 0.0216, factor = 2.4), miR-19b (p = 0.0261,
factor = 2.3), miR-24 (p = 0.0024, factor = 3.9), and
miR-34c (p = 0.0259, factor = 2.8) (Fig. 1b–e). None of
the miRNAs was individually able to discriminate PD and
MSA. Because of the age difference between the groups,
age was included as a possible confounding factor using
ANCOVA. This resulted in the loss of significance of the
difference for miR-205 (PD versus controls), but the dif-
ferences for the other targets were retained.
Diagnostic Value and Panels
ROC analysis was performed to determine the diagnostic
accuracy of targets that statistically differed between ei-
ther PD or MSA and controls. The area under the curve
(AUC), which indicates the accuracy, was moderate for all
targets for discrimination of PD or MSA from controls,
with an average AUC of 0.72 (±0.02) (Fig. 2a).
Binary logistic regression analysis was used to investigate
if combinations of miRNAs could improve their use as bio-
markers. A combination of miRNAs resulted in an improved
discrimination of PD from the control group (Fig. 2b)
Table 2 Number of predicted
targets and specification of targets
linked to PD/MSA for each
miRNA
MicroRNA Prediction software
TargetScan DIANA
Number of
predicted
targets
Targets already
linked to PD or MSA
Number of
predicted
targets
Targets already
linked to PD or MSA
miR-19a-3p 3968 PARK2, LRRK2, VPS35 1261 PARK2
miR-19b-3p 3968 PARK2, LRRK2, VPS35 1262 PARK2
miR-24-3p 6215 ATP13A2, VPS35 978 ATP13A2, EIF4G1
miR-30c-5p 4304 LRRK2, DNAJC13 1670 LRRK2, DNAJC13
miR-34b-3p 4165 SNCA, PARK2, VPS35 928 SNCA
miR-34c-5p 4374 SNCA, PLA2G6, SLC1A4 894 –
miR-132-5p 1230 – 54 –
miR-133b 2976 SNCA 1050 SNCA, DNAJC13
miR-148b-3p 4011 SNCA, PARK2, PARK7,
VPS35, HTRA2, SLC1A4
903 SNCA, PARK7
miR-205-5p 4413 LRRK2, HTRA2, SQSTM1 1371 LRRK2
SNCA synuclein alpha,ATP13A2ATPase 13A2, VPS35 retromer complex component, SQSTM1 sequestosome 1,
SLC1A4 solute carrier family 1 member 4,PLA2G6 phospholipase A2 group VI, PARK7 parkinsonism-associated
deglycase, PARK2 parkin RBR E3 ubiquitin protein ligase, LRRK2 leucine-rich repeat kinase 2, HTRA2 HtrA
serine peptidase 2, EIF4G1 eukaryotic translation initiation factor 4 gamma 1,DNAJC13DnaJ heat shock protein
family (Hsp40) member C13
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compared to single miRNAs. The created model included
miR-19a, miR-19b, miR-24, miR-30c, miR-34b, miR-133b,
and miR-205. The AUC from the ROC analysis increased to
0.96 (p value <0.0001, sensitivity of 96% and specificity of
92%, cutoff >−0.44, positive likelihood ratio = 13.5), suggest-
ing that the combination of these miRNAs could improve
diagnostic accuracy. A similar analysis was performed to gen-
erate a model for distinction of MSA from control (Fig. 2b),
which included miR-24 and miR-205. With this combination,
the diagnostic accuracy increased to an AUC of 0.86 (p value
<0.0001, sensitivity of 94% and specificity of 64%, cutoff
>−1.06, positive likelihood ratio = 2.64). Finally, by using
the combination of miR-133b and miR-148b, PD and MSA
could be discriminated (Fig. 2b); the ROC analysis showed a
moderate value with an AUC of 0.77 (p value = 0.001,
sensitivity of 82% and specificity of 67%, cutoff >−0.35, pos-
itive likelihood ratio = 2.56).
Correlation
In order to evaluate if there was a correlation between the
expression levels of the various miRNAs, we performed a
correlation analysis with Spearman’s rho test. We found 16
significant correlations between the miRNAs, and an over-
view of our findings is shown in Fig. 3. The most prominent
correlations were observed between miR-19a, miR-19b, miR-
30c, miR-34b, and miR-34c. We also studied correlations be-
tween miRNA levels and clinical parameters that were used
for evaluation of disease severity, such as the H&Y, UPDRS,
ICARS, and MMSE scores. We did not find any correlations
a b c
d e f
g h i
Fig. 1 Relative expression values of miRNAs in CSF from controls, PD,
andMSA patients. MiR-205 (a) and miR-24 (b) were able to discriminate
PD from non-neurological controls. Lower levels of miR-24 (b), miR-19a
(c), miR-19b (d), and miR-34c (e) compared to controls allowed the
discrimination of MSA from control patients. Data were analyzed using
ANOVA. *p < 0.05; **p < 0.001
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in the PD group between the miRNAs and the clinical param-
eters. However, in the MSA group, we observed the following
two negative correlations: miR-24 (r = −0.5, p = 0.045) and
miR-148b (r = −0.7, p = 0.012), both correlated to ICARS.
Discussion
The aim of our study was to identify miRNAs that could
serve as biomarkers of disease in CSF for either PD or
MSA and, ideally, that could discriminate between both
diseases. The selection of miRNAs was based on previous
publications, in which these miRNAs were identified as
potential biomarkers in blood, serum, brain tissue, or CSF.
We identified two potential biomarkers for PD (miR-24
and miR-205) and four miRNAs that could be biomarkers
for MSA (miR-19a, miR-19b, miR-24, and miR-34c).
MiRNA Biomarkers for PD
Our results showed an increase of miR-205 in CSF from PD
patients when compared to controls, which is in contrast with
previous findings in brain tissue of sporadic PD patients [17].
They observed a lower expression ofmiR-205 in brain regions
of 15 patients diagnosed with PD and increased levels of
leucine-rich repeat kinase 2 (LRRK2) protein, and this corre-
lation was also confirmed by functional studies with modula-
tion of this miRNA in cell lines and primary neurons in cul-
ture. These different observations remain yet unexplained.
We found lower levels of miR-24 in the CSF from both PD
and MSA patients as compared to control but no difference
between PD and MSA. This is also in contrast to results pre-
viously obtained, where miR-24 was found at higher concen-
trations in PD and MSA serum and increased in MSA in
comparison to PD [21]. This discrepancy could be due to the
differences in body fluids used (serum versus CSF), where
a
b
Fig. 2 a ROC curves of miRNAs with mean levels that were statistically
different between patient groups. The compared patient groups are
indicated between brackets. Areas under the curve (AUC) were 0.70 to
0.76, as indicated. b ROC curves of models created from binary logistic
regression to improve discrimination between groups. The model created
to differentiate PD from controls included miR-19a, miR-19b, miR-24,
miR-30c, miR-34b, miR-133b, and miR-205 and resulted in an AUC of
0.98. The model generated for comparison of MSA versus control
included miR-24 and miR-205 with an AUC of 0.86. For the model of
PD versus MSA, miR-133b and miR-148b were included and showed a
moderate value for accuracy with an AUC of 0.77
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serum levels could represent systemic changes, and CSF is
more closely related to neurodegeneration only. The ability
of miR-24 to discriminate PD or MSA from healthy controls
suggests that it may have potential as a biomarker for α-
synucleinopathies. Functional studies would be important to
understand the role of miR-24 in the pathology of α-
synucleinopathies.
MiRNA Biomarkers for MSA
In our study, miR-19a was identified at lower levels in MSA
compared to control, but no difference was observed between
PD and controls. This is not in line with previous findings of
decreased levels of miR-19a in serum from PD patients with
mutations in the LRRK2 gene compared to healthy controls in
a qPCR experiment [19]. This difference could be explained
by the absence of PD patients carrying LRRK2 mutation in
our patient selection and the difference in body fluids (serum
versus CSF). Lower levels of this miRNAwere also found in
CSF samples of PD in a small RNA sequencing experiment
[20]. Unfortunately, neither information about the selection of
patients was available in this study nor if the number of eryth-
rocytes or leukocytes in CSF was controlled for, which may
interfere with miRNA quantification in CSF [27, 28]. To our
knowledge, this is the first time that miR-19a was linked to
MSA. Among the predicted targets for miR-19a are the fol-
lowing three important genes already related to PD: PARK2
(parkin), LRRK2, and VPS35 (Table 2), but none of these has
previously been linked to MSA, which could be expected due
to the little evidence concerning a genetic cause of this
Fig. 3 Correlation analysis of all miRNAs among the three disease
groups. In total, 16 statistically significant correlations (p value below
0.05) were found, indicated with a red asterisk. Spearman’s rho
coefficient value (upper value (in blue)) and p value (lower value (in
green)) are indicated in the graphs
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disease. Our findings suggest that miR-19a could be a poten-
tial biomarker to differentiate MSA from controls, but func-
tional studies for target confirmation and validation in larger
cohorts remain necessary.
Similarly to miR-19a, CSF miR-19b levels were lower in
MSA compared to controls, which has not previously been
reported, although lower levels have also been found in serum
of idiopathic PD patients [19]. Lower expression levels in
serum were also found in patients with idiopathic rapid eye
movement sleep behavior disorder [33], which is often asso-
ciated to PD, MSA, or Lewy body dementia [34].
Downregulation of this miRNA was also observed in CSF
samples and in exosomes isolated from CSF from PD patients
compared to controls as observed in a small RNA sequencing
experiment [20, 35]. Our study did not reveal a reduction in
the concentration of this miRNA in CSF of PD patients, which
could be caused by differences in patient selection or differ-
ences in the way CSF had been processed or the number of
blood cells in the CSF that were included in the previous
studies. The similarities in predicted targets of miR-19a/b
(see Table 2), the previously published results and our results
of lower levels of both miRNAs in MSA (Fig. 1), and the
strong correlation between these miRNAs (Fig. 3) all suggest
that this miRNA family plays an important role in PD and
MSA pathophysiology, but validation in larger cohorts re-
mains necessary to obtain a better understanding of the role
of this miRNA in MSA or PD.
In our data, we observed lower levels of miR-34c in CSF
fromMSA patients. Interestingly, it has been described before
that miR-34b and miR-34c concentrations were lower in var-
ious brain regions from PD patients [15]. The same group also
found decreased brain levels of DJ-1 and parkin proteins,
which are both tightly linked to PD. A previous study identi-
fied that the p53 protein may activate the miR-34 family
(reviewed in [36]), and in addition, it has been suggested that
the α-synuclein, DJ-1, and parkin proteins may inhibit p53
activity [37–39]. Functional studies in human dopaminergic
cells confirmed that mRNA ofα-synuclein is a target of action
of miR-34b/c and that its inhibition leads to α-synuclein ag-
gregation [40]. The involvement of miR-34b/c in PD and
MSA is not completely understood but it is a potential thera-
peutic target, and their use as a biomarker requests a confir-
mation in larger cohorts.
Detection of Other miRNAs in CSF
We found similar levels of miR-30c, miR-133b, and miR-148b
in CSF samples of PD, MSA, and control. Our findings disagree
with previous descriptions of reduced levels of miR-30c in PD
serum [21] and peripheral blood mononuclear cell [18], de-
creased levels of miR-133b in PD brain tissue [16], and lower
levels of miR-148 in PD serum and increased levels in MSA
serum [21]. At the moment, the only explanation for this discrep-
ancy is the difference in sample types.
In general, we were not able to retrieve information on the
number of erythrocytes and leukocytes in the CSF samples stud-
ied in any of the previous publications, in which specific
miRNAs were suggested as potential biomarkers. We would like
to stress the importance to exclude CSF samples contaminated
by blood since this may affect CSF miRNA levels when future
studies are undertaken to evaluate the potential of miRNAs to
serve as a biomarker of diseases [27, 28]. We also recommend
attention to storage time and centrifugation of samples and use of
geometric means for normalization of the data to avoid possible
bias [29].
MiRNA Panels
Since each individual miRNA had limited value to serve as a
biomarker for either PD or MSA, given the relatively low
AUC, we analyzed if combinations of miRNAs could increase
the diagnostic accuracy. By applying binary logistic regres-
sion analysis including all miRNAs, we created models for
each pair of comparison. This resulted in the definition of
combinations of miRNAs that differentiated either PD
(AUC = 0.96) or MSA (AUC = 0.86) from controls at high
accuracy level and PD from MSA at moderate AUC (0.77).
Hence, our findings allow us to suggest three different panels
of miRNAs to be used as biomarkers for the distinction of PD,
MSA, and controls. However, confirmation in independent
cohorts will be necessary for final establishment of their diag-
nostic power.
Correlations of miRNAs with Other Parameters
Interestingly, we noted similarities in the predicted targets
(Table 2) of the various miRNAs that ended up in the regres-
sion models. The genes PARK2, LRRK2, and VPS35 ap-
peared as possible targets in almost all the miRNAs that were
enrolled in the model for differentiation of PD from controls.
No gene overlap was found in the predicted targets in the
model for differentiation of MSA compared to control, but
in the model that compared both diseases, α-synuclein was
shown to be a target for action of the two miRNAs.
We observed a strong correlation between miR-19a and miR-
19b, which was not surprising since they both belong to the same
family. Similarly, a strong correlation was observed for miR-34b
and miR-34c, which also belong to the same family.
We also studied correlations between miRNAs and clinical
parameters. Intriguingly, we found a negative correlation of miR-
24 and 148b with the ICARS score in MSA, but not in PD or
controls. This score is clinically used for evaluation of cerebellar
ataxia, which is a symptom that is predominantly observed in
MSA. Therefore, it is possible that genes regulated by miR-24
and 148b may control cerebellar functions and that deregulation
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of these miRNA levels may contribute to MSA. Further studies
will have to confirm this association, however.
Study Limitations
A few limitations apply to our study. First, unlike in mRNA
expression studies, there are no universally accepted reference
miRNAs to which target miRNAs can be normalized, since
miRNAs are tissue and disease specific. Therefore, we chose
to use the geometrical mean of two small RNAs to normalize
the data, but other methods and other reference miRNAs have
been used as well in other studies.
Second, differences between studies in sample processing
may affect the results of miRNA quantification, as
(micro)RNA levels are very low in CSF. Other techniques,
such as miRNA arrays or small RNA sequencing, offer great
possibilities to identify new miRNAs, but are not sensitive
enough to detect all miRNAs, whereas qPCR is very sensitive
but may yield results with high variability in different studies.
Third, the CSF samples we used were only collected for
research purposes creating a selection bias. Therefore, our
findings should be validated in larger cohorts and by other
centers to confirm the biomarker potential of the miRNAs.
Inclusion of other parkinsonian disorders would also yield
more detailed insight into the association of specific
miRNAs with neurodegenerative movement disorders.
Conclusion
MiRNAs play an important role in control of gene expression,
and their stability in body fluids offers a great opportunity to
use them as biomarkers. We identified two miRNAs that were
successful in distinguishing PD from controls and four
miRNAs that were able to differentiate MSA from controls.
Moreover, we also created three panels consisting of a com-
bination of CSF miRNAs that were able to discriminate either
PD or MSA from controls and also between both diseases
with high to medium accuracy levels. Therefore, these panels
of miRNAs may be used as biomarkers of disease.
Furthermore, in the MSA group, we observed a correlation
of twomicroRNAswith the ICARS score, a clinical parameter
used for quantification of cerebellar ataxia, a combination of
symptoms exclusive to MSA patients. Therefore, we suggest
further studies to investigate the role of these miRNAs in
control of cerebellar gene expression.
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